Skip to Content
 

News: Home Page Research

Study identifies protein’s role in chemotherapy resistance

Friday, July 21st, 2017

Researchers at Vanderbilt University Medical Center (VUMC) have discovered a protein that may lead to a new way to prevent resistance and improve outcomes for patients whose cancers have mutations in the tumor suppressor gene BRCA2. The protein, RADX, is a DNA-binding protein. It regulates the activity of an enzyme called RAD51, which helps repair tumor-promoting […]

Bile acids, microbiota and colon cancer

Monday, July 10th, 2017

Deoxycholic acid (DCA), a secondary bile acid that is increased by high dietary fat intake – a western diet – has been linked to intestinal carcinogenesis. In a previous study, Fang Yan, M.D., Ph.D., and colleagues showed that DCA accelerated the progression of adenoma to adenocarcinoma in mice that spontaneously develop intestinal adenomas. Now, the researchers […]

Alex’s Lemonade grant allows new engineering grad student to join neuroblastoma fight

Monday, July 10th, 2017

A grant from cancer research nonprofit Alex’s Lemonade Stand Foundation is allowing a Vanderbilt chemical and biomolecular engineering doctoral student to join the fight against pediatric neuroblastoma. Kyle Garland is spending his summer on a project titled Immunotherapeutic Targeting of the STING Pathway to Combat Neuroblastoma. He’s working with John Wilson, assistant professor of chemical […]

Genetics of lung cancer survival

Thursday, June 29th, 2017

African-Americans are more likely to die from lung cancer than whites and yet few studies of possible genetic factors that contribute to this disparity have been conducted. Melinda Aldrich, Ph.D., MPH, and colleagues conducted a first-of-its-kind genome-wide association study of lung cancer survival in 286 African-Americans enrolled in the Southern Community Cohort Study. Reporting recently […]

STINGing combination for cancer

Thursday, June 22nd, 2017

Cyclic dinucleotides (CDNs) are intracellular messengers produced in bacteria that can bind to and activate an immune-mediated signaling cascade called STING in mammalian cells. CDNs have shown antitumor activity in melanoma and breast tumors. Reporting this month in the journal Head & Neck, Young J. Kim, M.D., Ph.D., associate professor of Otolaryngology at Vanderbilt University, […]

PET imaging to predict tumor response

Thursday, June 15th, 2017

About 10 percent of patients with colorectal cancer express a mutated form of the signaling molecule BRAF, which may be targeted for treatment by selective BRAF inhibitors. PET (positron emission tomography) imaging using a standard glucose probe is not able to predict response to BRAF inhibitors. In addition to becoming dependent on glucose, cancer cells […]

Project reveals importance of cancer gene mutation testing

Friday, June 9th, 2017

An international genomic data-sharing consortium has analyzed nearly 19,000 patient genomic records and found that testing of patient tumors for relevant gene mutations often provides a roadmap for the use of effective therapies. The American Association for Cancer Research (AACR) Genomics Evidence Neoplasia Information Exchange (GENIE) is a multi-phase, multi-year data-sharing project launched in 2015 […]

Blood type link to cancer survival

Friday, May 19th, 2017

Ovarian cancer is the fifth leading cause of cancer deaths among women in the United States. Last year more than 14,000 deaths were reported. Despite treatment advances, overall five-year survival after diagnosis remains abysmally low at 45 percent. ABO blood type has been linked to multiple diseases including pancreatic and ovarian cancer risk. Two small […]

Researchers seek best ways to increase HPV vaccination rates

Friday, May 12th, 2017

Tennessee has one of the lowest human papillomavirus (HPV) vaccination rates in the nation, and investigators at Vanderbilt University Medical Center (VUMC) are hoping to change this by improving the way medical providers present these vaccines to patients and by improving patient and patient family education. “HPV is the most commonly sexually transmitted infection in […]

Study examines new breast cancer drug combination

Thursday, April 27th, 2017

A study led by Vanderbilt-Ingram Cancer Center (VICC) investigators suggests a drug combination which includes a PDK1 protein blocker may be more effective for breast cancer that has become resistant to cyclin-dependent kinase (CDK4/6) targeted therapy. The study, published in Cancer Research, was led by first author Valerie Jansen, M.D., Ph.D., instructor in Medicine. Valerie […]

Next Page »« Previous Page